These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke. Nakashima T; Toyoda K; Koga M; Matsuoka H; Nagatsuka K; Takada T; Naritomi H; Minematsu K Int J Stroke; 2009 Dec; 4(6):425-31. PubMed ID: 19930051 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis. Li X; Ling L; Li C; Ma Q Medicine (Baltimore); 2017 May; 96(18):e6667. PubMed ID: 28471961 [TBL] [Abstract][Full Text] [Related]
19. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making]. Kakuda W; Abo M Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605 [TBL] [Abstract][Full Text] [Related]
20. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM; Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]